^
Association details:
| Biomarker: | RARA overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | azacitidine (DNA methylation inhibitor) + Amnolake (tamibarotene) (RARα agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
Published date:
04/28/2023
Excerpt:
The combination of oral tamibarotene plus azacitidine was evaluated in a phase 2 clinical study in 51 newly diagnosed unfit patients with AML identified as RARA-positive...The presence of RARA overexpression was characterized as RARA-positive...The 18 response-evaluable RARA-positive patients were evaluated for best OR (response definitions and results in Figure 3). The ORR was 67% (12/18), with a CR/CRi rate of 61% (9 CR, 2 CRi), a CR rate of 50%...
DOI:
10.1182/bloodadvances.2022008806
